Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Insiders here have filed 16 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
Loses money on what it sells.
- Revenue
- $325.0M
- Net income
- -$289.5M
- Net margin
- -89.1%
Little or no net debt.
- Total debt
- $46.0M
- Cash
- $110.8M
- Debt / equity
- 0.06
Comfortably covers what is due within a year.
- Current assets
- $464.3M
- Current liabilities
- $106.8M
- Current ratio
- 4.35
Consumes cash and must keep raising it.
- Operating cash flow
- -$264.2M
- Free cash flow
- -$296.4M
- FCF margin
- -91.2%
Burning cash with under a year of runway — expect a raise.
- Shares outstanding
- 450.2M
- Share growth (1y)
- 34.6%
- Cash runway
- 5 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
IOVA Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 99.31 M | 71.43 M | 86.77 M | 67.45 M | 59.95 M | 49.32 M |
| Revenue Growth (YoY) | 65.65 % | 44.82 % | 17.74 % | 15.20 % | 92.73 % | 6798.46 % |
| Cost of Revenue | 43.59 M | 42.50 M | 43.11 M | 38.48 M | 48.88 M | 42.72 M |
| Gross Profit | 55.72 M | 28.93 M | 43.66 M | 28.98 M | 11.07 M | 6.61 M |
| SG&A Expense | 39.27 M | 38.95 M | 36.40 M | 34.55 M | 37.57 M | 43.80 M |
| R&D Expense | 58.85 M | 62.49 M | 71.20 M | 75.17 M | 77.93 M | 75.97 M |
| Operating Expenses | 107.62 M | 109.97 M | 117.12 M | 118.74 M | 124.84 M | 127.83 M |
| Operating Income | -51.91 M | -81.04 M | -73.46 M | -89.76 M | -113.77 M | -121.22 M |
| Pretax Income | -48.69 M | -79.71 M | -71.72 M | -93.66 M | -109.67 M | -118.00 M |
| Tax Provision | -1.37 M | -665.00 K | 184.00 K | -2.40 M | 1.99 M | -1.84 M |
| Net Income | -47.31 M | -79.05 M | -71.90 M | -91.25 M | -111.66 M | -116.16 M |
| EPS (Basic) | -0.11 | -0.19 | -0.18 | -0.25 | -0.33 | -0.36 |
| EPS (Diluted) | -0.11 | -0.19 | -0.18 | -0.25 | -0.33 | -0.36 |
| Shares Outstanding | 450.19 M | 418.51 M | 406.97 M | 364.04 M | 334.51 M | 322.87 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.